YU59403A - Androgeni 7-supstituisani 11-halogenovani steroidi - Google Patents

Androgeni 7-supstituisani 11-halogenovani steroidi

Info

Publication number
YU59403A
YU59403A YU59403A YUP59403A YU59403A YU 59403 A YU59403 A YU 59403A YU 59403 A YU59403 A YU 59403A YU P59403 A YUP59403 A YU P59403A YU 59403 A YU59403 A YU 59403A
Authority
YU
Yugoslavia
Prior art keywords
androgenic
substituted
halogen
halogen steroids
steroids
Prior art date
Application number
YU59403A
Other languages
English (en)
Inventor
Rolf Bohlmann
Hermann Kunzer
Reinhard Nubbemeyer
Dieter Zopf
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU59403A publication Critical patent/YU59403A/sh
Publication of RS50740B publication Critical patent/RS50740B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0025—Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pronalazak se odnosi na 11ГЎ-halogen steroide sa opštom formulom (I), pri čemu je R11 halogen, X-Y-Z predstavlja grupu jedne ili dve strukture CH=C-C ili CH2-C=C a drugi radikali imaju značenje koje je naznačeno u zahtevima, takodje na proizvodnju i upotrebu ovih jedinjenja za proizvodnju farmaceutskih sredstava kao i farmaceutskih preparata koji sadrže 11ГЎ-halogen steroide.[The invention relates to 11ГЎ-halogen steroids with general formula (I), whereby R11 is halogen, X-Y-Z represents a group with one of the two structures CH=C-C or CH2-C=C and the other radicals have the meaning that is indicated in the claims, also the production and use of these compounds for the production of pharmaceutical agents as well as pharmaceutical preparations that contain 11ГЎ-halogen steroids.
YUP-594/03A 2001-01-24 2002-01-24 Androgeni 7-supstituisani 11-halogenovani steroidi RS50740B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10104327A DE10104327A1 (de) 2001-01-24 2001-01-24 11beta-Halogensteroide, deren Herstellung und Verwendung zur Herstellung von Arzneimitteln sowie 11beta-Halogensteroide enthaltende pharmazeutische Präparate

Publications (2)

Publication Number Publication Date
YU59403A true YU59403A (sh) 2006-08-17
RS50740B RS50740B (sr) 2010-08-31

Family

ID=7672351

Country Status (35)

Country Link
US (1) US7361645B2 (sh)
EP (1) EP1353938B1 (sh)
JP (1) JP4339591B2 (sh)
KR (1) KR100728088B1 (sh)
CN (1) CN1234721C (sh)
AR (1) AR053299A1 (sh)
AT (1) ATE386045T1 (sh)
AU (1) AU2002238516B2 (sh)
BG (1) BG66133B1 (sh)
BR (1) BR0206653A (sh)
CA (1) CA2434187C (sh)
CY (1) CY1110377T1 (sh)
CZ (1) CZ303553B6 (sh)
DE (2) DE10104327A1 (sh)
DK (1) DK1353938T3 (sh)
EA (1) EA006674B1 (sh)
EE (1) EE05274B1 (sh)
ES (1) ES2300431T3 (sh)
HK (1) HK1064678A1 (sh)
HR (1) HRP20030661B1 (sh)
HU (1) HUP0303020A3 (sh)
IL (2) IL156807A0 (sh)
MX (1) MXPA03006578A (sh)
NO (1) NO325754B1 (sh)
NZ (1) NZ527041A (sh)
PE (1) PE20020848A1 (sh)
PL (1) PL207582B1 (sh)
PT (1) PT1353938E (sh)
RS (1) RS50740B (sh)
SK (1) SK287444B6 (sh)
TW (1) TWI333494B (sh)
UA (1) UA75907C2 (sh)
UY (1) UY27133A1 (sh)
WO (1) WO2002059139A1 (sh)
ZA (1) ZA200306537B (sh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10234525A1 (de) * 2002-07-25 2004-02-05 Schering Ag Zusammensetzung, enthaltend ein androgenes 11ß-Halogensteroid und ein Gestagen sowie männliches Kontrazeptivum auf Basis dieser Zusammensetzung
PL373808A1 (en) * 2002-07-24 2005-09-19 Schering Aktiengesellschaft Microbiological method for the production of 7 alpha-substituted 11 alpha-hydroxysteroids
DE10233723A1 (de) 2002-07-24 2004-02-12 Schering Ag Mikrobiologische Verfahren zur Herstellung von 7α-substituierten 11α-Hydroxysteroiden, daraus herstellbare 7α,17α-substituierte 11β-Halogensteroide, deren Herstellungsverfahren und Verwendung sowie pharmazeutische Präparate, die diese Verbindungen enthalten, sowie daraus herstellbare 7α-substituierte Estra-1,3,5(10)-triene
CN1671394A (zh) * 2002-07-25 2005-09-21 舍林股份公司 包含雄激素性11β－卤素甾体和孕激素的组合物以及基于该组合物的雄性避孕药
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7879357B2 (en) * 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
CN106146592B (zh) * 2014-10-08 2017-10-24 常州大学 一种合成睾酮方法
TWI530504B (zh) * 2014-12-01 2016-04-21 臺灣永光化學工業股份有限公司 烷基酸睾酮化合物之合成方法
US20220411460A1 (en) * 2021-06-29 2022-12-29 Board Of Regents, The University Of Texas System Modified glucocorticoids

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB863661A (en) * 1958-06-06 1961-03-22 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
CH380118A (de) * 1959-06-17 1964-07-31 Ciba Geigy Neue Halogenandrostenverbindungen und Verfahren zu deren Herstellung
FR1489519A (fr) * 1965-08-16 1967-07-21 Glaxo Lab Ltd Procédé de préparation de nouveaux 19-nor-stéroïdes et produits obtenus
GB1159434A (en) * 1965-08-16 1969-07-23 Glaxo Lab Ltd 11beta&;-Fluoro-19-nor-Steroids
US3665021A (en) * 1966-07-29 1972-05-23 Glaxo Lab Ltd 9alpha-unsubstituted-11beta-chloro-l9 nos-steroids
GB1260463A (en) * 1968-01-29 1972-01-19 Glaxo Lab Ltd 11beta-BROMO-19-NOR-STEROIDS
DE2410442A1 (de) * 1974-03-01 1975-09-11 Schering Ag Verfahren zur herstellung von 11-fluorandrostenen
DE2410443A1 (de) * 1974-03-01 1975-09-11 Schering Ag 11beta-fluor-androstene
DE3214690A1 (de) * 1982-04-16 1983-10-27 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-chlor-(delta)(pfeil hoch)1(pfeil hoch)(pfeil hoch)5(pfeil hoch)-steroide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
GB8721384D0 (en) * 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
US5342834A (en) * 1989-04-07 1994-08-30 The Population Council, Inc. Method for androgen supplementation
US20020012694A1 (en) * 1997-09-17 2002-01-31 Alfred J. Moo-Young Transdermal administration of ment
US6767902B2 (en) * 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
WO2000053619A1 (en) * 1999-03-08 2000-09-14 Akzo Nobel N.V. 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
EP1212345B1 (en) * 1999-04-06 2003-08-06 Akzo Nobel N.V. Orally active 7-alpha-alkyl androgens
DE19959696A1 (de) * 1999-12-08 2001-06-21 Jenapharm Gmbh Ungesättigte 14,15-Cyclopropano-Androstane, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
CA2434187C (en) 2009-06-16
UY27133A1 (es) 2002-07-31
DE60224982D1 (de) 2008-03-27
EE200300346A (et) 2003-12-15
ZA200306537B (en) 2004-09-08
PL361730A1 (en) 2004-10-04
DK1353938T3 (da) 2008-05-26
EA200300756A1 (ru) 2004-02-26
NO325754B1 (no) 2008-07-14
CN1487950A (zh) 2004-04-07
US7361645B2 (en) 2008-04-22
HUP0303020A2 (hu) 2003-12-29
BG66133B1 (bg) 2011-06-30
SK287444B6 (sk) 2010-09-07
EA006674B1 (ru) 2006-02-24
EE05274B1 (et) 2010-02-15
HK1064678A1 (en) 2005-02-04
CY1110377T1 (el) 2015-04-29
NZ527041A (en) 2005-02-25
JP4339591B2 (ja) 2009-10-07
IL156807A0 (en) 2004-02-08
ES2300431T3 (es) 2008-06-16
CZ20032006A3 (cs) 2004-01-14
US20050075322A1 (en) 2005-04-07
TWI333494B (en) 2010-11-21
PT1353938E (pt) 2008-04-29
AR053299A1 (es) 2007-05-02
KR100728088B1 (ko) 2007-06-14
AU2002238516B2 (en) 2007-08-23
HUP0303020A3 (en) 2012-03-28
BR0206653A (pt) 2004-02-03
UA75907C2 (en) 2006-06-15
EP1353938A1 (en) 2003-10-22
CA2434187A1 (en) 2002-08-01
BG108023A (bg) 2004-02-27
NO20033321L (no) 2003-09-24
SK9542003A3 (en) 2003-12-02
PL207582B1 (pl) 2011-01-31
PE20020848A1 (es) 2002-10-26
ATE386045T1 (de) 2008-03-15
IL156807A (en) 2008-08-07
CN1234721C (zh) 2006-01-04
DE60224982T2 (de) 2009-04-09
DE10104327A1 (de) 2002-07-25
HRP20030661A2 (en) 2005-06-30
HRP20030661B1 (en) 2011-10-31
RS50740B (sr) 2010-08-31
MXPA03006578A (es) 2003-09-22
KR20030081391A (ko) 2003-10-17
CZ303553B6 (cs) 2012-12-05
NO20033321D0 (no) 2003-07-23
JP2004517153A (ja) 2004-06-10
WO2002059139A1 (en) 2002-08-01
EP1353938B1 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MY132106A (en) New pyridazin-3(2h)-one derivatives
SE9904505D0 (sv) Novel compounds
PT1263725E (pt) Novos compostos
IS6658A (is) Ný efnasambönd
DE60112974D1 (en) Carbolinderivate
AU1529402A (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
AU2003228770A1 (en) Substituted pyrazolopyrimidines
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
DE60216233D1 (en) Carbolinderivate
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
CY1110377T1 (el) Ανδρογονα 7-υποκατεστημενα 11-αλογονουχα στεροειδη
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
MXPA04003755A (es) Endoprotesis vasculares.
HK1055304A1 (en) Tricyclic imidazopyridines
MXPA04004981A (es) Derivados de piperazina para uso como antagonistas del receptor ccr-3 en tratamiento de asma.
TW200612962A (en) Estriol and estetrol prodrugs
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
DE60201074D1 (en) Pyrazolopyridinderivate
DE60226313D1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
MXPA04001977A (es) Antagonistas v de receptor ccr-3.
DE60220699D1 (de) Tibolonformulierungen
MXPA05008833A (es) D-homoestra-1,3,5(10)-trien-3-il-sulfamatos 2-sustituidos con actividad antitumoral.